Aug 11, 2020
Soliton Reports Second Quarter 2020 Results
Jun 09, 2020
Soliton To Announce Results of Pivotal Cellulite Clinical Trial
May 18, 2020
Soliton Announces Pivotal Cellulite Clinical Trial Results to be Presented at AAD Virtual Meeting June 12-14
May 14, 2020
Soliton Reports First Quarter 2020 Results
Apr 08, 2020
Soliton Granted New Key Patent for FDA Cleared RAP Technology
Mar 23, 2020
Soliton to Present Pivotal Cellulite Clinical Trial Results at Virtual AAD 2020 Annual Meeting
Mar 20, 2020
Lead Investigator Evaluates Next-Step for Soliton Pivotal Cellulite Clinical Data
Mar 09, 2020
Soliton signs Agreement with Global Manufacturer Sanmina
Feb 11, 2020
Soliton Files Special 510(k) with FDA for its Generation II RAP Device
Feb 06, 2020
Soliton Advances Market Launch Preparation; Appoints James Bucher as Senior Sales Consultant
Jan 27, 2020
Soliton Announces Positive Data from Extended Keloid and Hypertrophic Scar Trials
Jan 07, 2020
Soliton Appoints Robert "Joe" Mills as Vice President of Supply Chain
Dec 18, 2019
Soliton Announces Successful Completion of Safety Testing at SGS to Support FDA Filing for Second Generation Device
Dec 10, 2019
Soliton Appoints Mary Stoll as Senior Director of Clinical Development
Dec 03, 2019
Soliton Initiates Significant Step Towards Commercialization
Nov 21, 2019
Soliton and Emphysys Enter Into a 3-year Development Agreement
Oct 15, 2019
Soliton's FDA Cleared RAP Device is Granted Two Additional Key Patents
Oct 01, 2019
Soliton Completes Keloid POC Clinical Trial Treatments
Sep 17, 2019
Soliton Completes Trial Enrollment and Conducts Initial Site Training to Start Keloid Trial
Sep 10, 2019
Soliton Announces Site Selected for Clinical Trial to Treat Fibrotic Scars